Retatrutide Cost & How to Get It

Retatrutide availability and cost at a glance

How to Access Retatrutide Today

The TRIUMPH Program

• TRIUMPH-4 (obesity and osteoarthritis): Completed. Results announced December 2025.
• TRIUMPH-6 (weight maintenance): Active, but no longer recruiting (643 participants enrolled).
• Other TRIUMPH trials: Some may still be recruiting participants. Availability changes frequently.

How to Find Open Trials

Search for active retatrutide trials on ClinicalTrials.gov:

When reviewing trial listings, look for studies with a status of "Recruiting" or "Not yet recruiting." Each listing includes eligibility criteria, study locations, and contact information for enrollment.

Key things to know about clinical trial participation:

• The drug is free. Participants are not charged for the investigational medication.
• You may receive a placebo. Most trials are randomized and placebo-controlled, meaning there is a chance you will not receive retatrutide.
• There are strict eligibility criteria. Trials typically require specific BMI thresholds, health conditions, or other qualifications.
• Visits are frequent. You will need to attend regular study visits at a trial site for the duration of the study.
• Locations are limited. Not all cities or regions have trial sites.

Current GLP-1 Drug Pricing (2026)

While retatrutide is not yet available, several GLP-1 receptor agonist drugs are FDA-approved and currently prescribed for weight loss and type 2 diabetes. If you are considering weight loss medication now, here is what the current landscape looks like.

Semaglutide — Ozempic & Wegovy (Novo Nordisk)

Tirzepatide — Mounjaro & Zepbound (Eli Lilly)

The Medicare negotiated prices (~$245/month) were established through a Trump administration agreement announced in November 2025 and represent a significant reduction from list prices for Medicare Part D enrollees.

What Retatrutide Might Cost

Eli Lilly has not announced pricing for retatrutide. The drug has not been approved, does not have a brand name, and pricing will not be finalized until closer to launch. That said, several factors provide a reasonable basis for estimates.

Analyst Estimates

If Lilly positions retatrutide as a premium "next-generation" therapy — which the clinical data would support, given the superior weight loss results — it could be priced higher than Zepbound. However, competitive pressure from Novo Nordisk's pipeline and the expansion of Medicare negotiated pricing may limit how much of a premium Lilly can charge.

Lilly's Pricing Pattern

Eli Lilly has established a pattern with Zepbound that is likely to carry over to retatrutide:

• High list price ($1,000+/month), consistent with industry norms
• Competitive direct-to-consumer pricing through LillyDirect, undercutting retail pharmacy costs
• Savings programs for commercially insured patients
• Aggressive engagement with Medicare negotiations to secure broad coverage

Lilly has been more transparent about consumer pricing than many pharmaceutical companies, and the success of LillyDirect for Zepbound suggests they will use a similar channel for retatrutide.

What This Means Practically

These are estimates, not confirmed prices. Actual pricing will depend on FDA-approved indications, competitive dynamics at the time of launch, and Lilly's commercial strategy.

Insurance Coverage Landscape

Insurance coverage for GLP-1 drugs used for obesity has been historically limited, but the landscape is shifting.

What Is Covered Today

• Medicare Part D now covers Wegovy (semaglutide) for heart disease prevention, following FDA approval of a cardiovascular indication. Medicare negotiated prices for both semaglutide and tirzepatide are approximately $245/month.
• Commercial insurance coverage varies widely. Many plans cover GLP-1 drugs for type 2 diabetes but exclude or restrict coverage for obesity alone.
• Prior authorization is common. Most insurers require documentation of BMI, failed dietary interventions, and sometimes comorbidities before approving coverage.
• Step therapy may be required, meaning you may need to try and fail on a less expensive drug before your insurer will cover a newer one.
• Employer-sponsored plans are increasingly adding obesity drug coverage, but adoption is uneven.

What Retatrutide Coverage Might Look Like

Retatrutide's insurance coverage will depend on its FDA-approved indications:

• Obesity indication: Coverage will likely mirror current Zepbound coverage — available through some commercial plans, often with prior authorization and step therapy requirements.
• Type 2 diabetes indication: Broader coverage, as insurers have historically been more willing to cover GLP-1 drugs for diabetes.
• Additional indications (osteoarthritis, sleep apnea, MASH): If retatrutide receives FDA approval for conditions beyond obesity and diabetes, it could unlock insurance coverage pathways that are not available for current GLP-1 drugs.
• Medicare: If retatrutide receives a cardiovascular or other preventive indication, Medicare Part D coverage is likely. Government-negotiated pricing would apply.

The insurance landscape for obesity drugs is evolving. By the time retatrutide reaches the market (likely 2027), coverage may be substantially broader than it is today.

Telehealth Platforms for Existing GLP-1 Drugs

If you are interested in weight loss medication and cannot wait for retatrutide, several telehealth platforms currently prescribe FDA-approved GLP-1 drugs. These may be an option while retatrutide completes the approval process.

Current telehealth options include:

• LillyDirect — Eli Lilly's direct-to-consumer platform for Zepbound (tirzepatide). Includes consultation, prescription, and home delivery at $349-499/month.
• GoodRx — Offers a $39/month telemedicine subscription and introductory pricing of $199/month for Ozempic/Wegovy.
• Hims & Hers, Ro, Found, Calibrate — Various telehealth platforms offering weight loss programs that may include GLP-1 prescriptions, with prices and services varying by platform.

Why You Should NOT Buy Gray Market Retatrutide

These products are typically sold online, labeled "for research purposes only," and marketed through social media, forums, and peptide vendor websites. They are not manufactured under pharmaceutical-grade conditions, are not FDA-regulated, and are not intended for human use.

The Risks

• Unknown purity. Even a 1% impurity may include lipopolysaccharide (LPS), a bacterial endotoxin that causes systemic inflammation. Repeated injections of impure peptides can trigger immune responses.
• No quality control. There is no standardized manufacturing process, no batch testing, and no regulatory oversight. What is in the vial may differ from what is on the label.
• May not contain retatrutide. Gray market products can be mislabeled, underdosed, overdosed, or contain entirely different substances.
• No medical supervision. Retatrutide requires careful dose titration. In clinical trials, participants are escalated through increasing doses over weeks under medical monitoring. Self-administering without this supervision increases the risk of severe side effects.
• Potential autoimmune effects. Repeated injection of impure peptides can sensitize the immune system, potentially causing autoimmune reactions.

Regulatory Direction

Legislation is being considered that may make purchasing gray market peptides illegal for consumers, not just sellers. Part of the motivation is to protect pharmaceutical patents — including Lilly's retatrutide patent — but the public health rationale is straightforward: injecting unregulated substances is risky.

Compounding Pharmacies and Retatrutide

Compounding pharmacies have played a significant role in the current GLP-1 market. Compounded versions of semaglutide were widely available at lower cost when the branded drugs were in shortage. However, the FDA has been cracking down on compounded GLP-1 products as supply shortages resolve.

Can Retatrutide Be Compounded?

1. Retatrutide is not FDA-approved. Compounding pharmacies can only compound copies of FDA-approved drugs. Since retatrutide has no FDA approval, there is no legal basis for compounding it.
2. Compounding requires a shortage declaration. Even after FDA approval, compounding pharmacies can typically only produce copies of a drug if the FDA has declared an official shortage of that drug. With Lilly's manufacturing investments, a shortage declaration for retatrutide is not guaranteed.

The compounding landscape for GLP-1 drugs is in flux. Compounded semaglutide availability has been curtailed as Novo Nordisk's supply has stabilized. Compounded tirzepatide has been similarly restricted as Lilly resolved its shortage. The regulatory trend is toward tighter restrictions on compounding, not looser ones.

If and when retatrutide is FDA-approved, the possibility of compounded versions will depend entirely on whether an official shortage is declared — and Lilly will have every incentive to ensure supply meets demand.

The 2026 Peptide Reclassification

Retatrutide is an investigational new drug — a completely different regulatory category from compounded peptides. It cannot be compounded, purchased, or prescribed outside of FDA-authorized clinical trials regardless of the reclassification outcome.

International Availability

Retatrutide is being developed primarily through the U.S. regulatory pathway. International availability will follow, but with significant delays.

These timelines are estimates based on typical regulatory lag between FDA approval and international submissions. As of August 2026, no international regulatory submissions for retatrutide are publicly known.

International patients who are interested in retatrutide may want to:

• Check ClinicalTrials.gov for trial sites outside the United States
• Discuss currently available GLP-1 drugs with their healthcare provider
• Monitor this page and the retatrutide FDA approval timeline 2026–2028 for updates on international regulatory filings

Frequently Asked Questions

Sources

• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• Eli Lilly and Company. (2026). Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 results, investigational status, and planned U.S. submission. Press release.
• ClinicalTrials.gov. Retatrutide interventional studies. Search results.
• GoodRx. Weight loss drug pricing and telehealth subscriptions. GoodRx.com.
• LillyDirect. Zepbound pricing and direct-to-consumer access. LillyDirect.com.
• U.S. Centers for Medicare & Medicaid Services. Medicare Part D negotiated drug prices. CMS.gov.